Market Overview
- The Global Carcinoembryonic Antigen (CEA) Market is expected to grow at a high CAGR during the forecasting period (2020-2027).
- Carcinoembryonic antigen (CEA) is a glycoprotein normally found in embryonic entodermal epithelium. The CEA blood level may be increased in certain types of cancer and non-cancerous (benign) conditions. A (CEA) test measures the amount of this protein that may appear in the blood of some people who have certain kinds of cancers, especially cancer of the large intestine (colon and rectal cancer).
Download free sample: https://www.datamintelligence.com/download-sample/carcinoembryonic-antigen-market
Market Dynamics
- The growth of the global carcinoembryonic antigen (CEA) market is driven by several factors such as, rising incidence rate for cancer, growing demand for minimally invasive diagnostics procedures, and increasing geriatric population.
- According to the WHO, cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Approximately 70% of deaths from cancer occur in low- and middle-income countries. The number of cancer cases diagnosed worldwide each year has risen tremendously, due to increasing life expectancy that will eventually result in millions of people being diagnosed in their lifetime, hence driving the growth of the market. Around one third of deaths from cancer are due to the 5 leading behavioral and dietary risks: high body mass index, low fruit and vegetable intake, lack of physical activity, tobacco use, and alcohol use. Tobacco use is the most important risk factor for cancer and is responsible for approximately 22% of cancer deaths. All these factors are expected to boost the market growth during the forecast period.
- The development of novel combination biomarkers and initiatives by the government concerning improved diagnostic rates are likely to open growth avenues for CEA market. The advent of various tumor markers, which can be used along with CEA to monitor or diagnose colorectal cancer is predicted to influence the market growth positively.
- Carcinoembryonic antigen is the recurrent indicator in asymptomatic patients and presently the most cost-effective assessment for preclinical detection of illness. The test is beneficial for the primary detection of liver metastasis in patients with diagnosed colorectal cancer.
- However, ineffective approach for cancer detection at initial stage and lack of awareness are restraining the carcinoembryonic antigen market growth.
Market Segmentation Analysis
- On the basis of application, the global, carcinoembryonic antigen (CEA) market is segmented into gastrointestinal cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, and thyroid cancer. Gastrointestinal cancer held the largest market share in 2018 and estimated to dominate over the forecast period. (2020-2027). Gastrointestinal cancer includes various types of cancer such as colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, esophageal cancer, and others. It is one of the most common cancers worldwide. Over 70% of gastrointestinal cancer cases occur in developing countries affecting majority of the population. Colorectal cancer is estimated to be dominant application within gastrointestinal cancers, owing to the growing demand for minimally invasive cancer diagnosis methods, increasing influence of sedentary lifestyle in adult population, and rising public awareness associated with early cancer diagnosis. In 2017, there were about 95,520 new cases of colon cancer and 39,910 cases of rectal cancer diagnosed in the US. The numbers of colon cancer are fairly equal in men (47,700) and women (47,820). According to the World Health Organization (WHO), the number of deaths is expected to rise in all countries for both colon and rectal cancer by 60.0% and 71.5% until 2035, respectively, due to population growth and ageing.
- By gender, carcinoembryonic antigen market for males held the largest market share in 2018. According to the American Cancer Society, about half of men get cancer at some point of their lives, as compared to one-third of women population, hence driving the market size. In addition, based on a study published in the European Journal of Epidemiology in 2012, researchers concluded that cancer affects men more often than women owing to certain risk factors, such as smoking and drinking. The female segment is expected to grow at a significant CAGR during the forecast period (2020-2027), as majority of females are suffering from breast cancer globally, and it is the most common cancer affecting the women population, hence boosting the market growth.
Market Geographical Analysis
- North America is dominating the global carcinoembryonic antigen (CEA) market accounting for largest market share in 2018, owing to the rising incidence of cancer in this region, growing awareness about detecting cancer at an early stage and advanced health care services for cancer therapeutics. For instance, according to American Cancer Society, in 2019, 1,762,450 new cancer cases and 606,880 cancer deaths were projected to occur in the United States. According to the National Cancer Institute, an estimated 1,735,350 new cases of cancer were diagnosed in the U.S. in 2018. Also, the U.S. has seventh highest cancer rate worldwide with about 300 of every 100,000 Americans developing cancer each year.
- The Asia-Pacific carcinoembryonic antigen (CEA) market is growing at the fastest growth rate during the forecast period (2020-2027), owing to increasing prevalence of cancer in countries including India and China. India market is estimated to grow substantially at a CAGR over the forecast period. According to the National Cancer Registry Programmed, Indian Council of Medical Research, NCRP (ICMR), the total cancer cases are projected to increase from 979,786 cases in 2010 to 1,148,757 cases by 2020. The tobacco-related cancers for males are estimated to go up from 190,244 in the year 2010 to 225,241 in the year 2020. Similarly, the female cases will go up from 75,289 in year 2010 to 93,563 in the year 2020. For the year 2010, the number of cancer cases related to digestive system, for both males and females, are estimated to be 107,030 and 86,606 respectively. Gynecological-related cancers are estimated to go up from 153,850 in 2010 to 182,602 in 2020. Among males and females, cancer of breast alone is expected to cross the figure of 100,000 by the year 2020. Hence, with rising number of cancer cases, the demand for the treatment in increasing, thus driving the growth of the market in this region.
Market Competitive Trends
- The carcinoembryonic antigen (CEA) market is competitive with few major players competing to gain market share. Some of the major players in the global carcinoembryonic antigen (CEA) market include: Quest Diagnostics, F. Hoffman LA Roche, GenWay Biotech Inc., Correlogic Systems, Inc., Abbott Laboratories, Boster Biological Technology, RayBiotech, Inc., Omega Diagnostics Group PLC, Creative Diagnostics, among others.
- The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the carcinoembryonic antigen (CEA) market globally. For instance,
- In October 2019, SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach with the aim to improve cancer surgery and clinical outcomes for patients, announced that the first US patient has been recruited into its on-going pivotal Phase 3 clinical trial evaluating its investigational imaging agent SGM-101 in patients undergoing colorectal cancer (CRC) surgery. SGM-101 is a tumor-specific antibody conjugated to a dye (fluorophore) that fluoresces under near-infra-red light; it selectively targets a marker on the cancer cell surface known as carcinoembryonic antigen (CEA), which is overexpressed by more than 95% of colorectal cancer cells.
- In April 2019, Kitov Pharma, an innovative pharmaceutical company developing first-in-class combination oncology therapies, acquired FameWave Ltd., following a clinical collaboration agreement between FameWave and Bristol Myers Squibb for their planned Phase 1/2 clinical trials to evaluate the combination of CM-24, a monoclonal antibody targeting the novel immune checkpoint carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) with nivolumab (Opdivo®), a PD-1 inhibitor, in patients with non-small cell lung cancer (NSCLC).
- In February 2019, RedPath Integrated Pathology, Inc., a leader in molecular diagnostics, launched a new, patent-pending, customized test to accurately measure carcinoembryonic antigen (CEA) in all pancreatic cyst fluids. Unlike routinely used, commercially available CEA assays, AccuCEA™ provides accurate results, even in pancreatic cyst fluid specimens with limited volume and/or high viscosity. Furthermore, AccuCEA provides physicians with more options in the diagnostic work-up of patients by preserving precious fluid and making it available for additional tests.
View full report: https://www.datamintelligence.com/research-report/carcinoembryonic-antigen-market
Enquiry before buying: https://www.datamintelligence.com/enquiry/carcinoembryonic-antigen-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com
The latest trending report Global Carcinoembryonic Antigen (CEA) Market 2020 by Manufacturers Regions Type and Application Forecast to 2025 offered by DecisionDatabases.com is an informative study covering the market with detailed analysis.
The report will assist reader with better understanding and decision making.The global Carcinoembryonic Antigen (CEA) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.9% in the forecast period of 2020 to 2025 and will expected to reach USD 2103.4 million by 2025, from USD 1804.5 million in 2019.The Carcinoembryonic Antigen (CEA) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/31935-carcinoembryonic-antigen-cea-market-analysis-reportThe major players covered in Carcinoembryonic Antigen (CEA) are:Roche DiagnosticsAbbott DiagnosticsQuest DiagnosticsBy Type, Carcinoembryonic Antigen (CEA) market has been segmented into:CD66aCD66bCD66cCD66dCD66eCD66fBy Application, Carcinoembryonic Antigen (CEA) has been segmented into:Colorectal CancerPancreatic CancerOvarian CancerBreast CancerThyroid CancerOthersThe report offers in-depth assessment of the growth and other aspects of the Carcinoembryonic Antigen (CEA) market in important countries (regions), including:North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)South America (Brazil, Argentina, Colombia)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)Download Free Sample Report of Global Carcinoembryonic Antigen (CEA) Market @ https://www.decisiondatabases.com/contact/download-sample-31935There are 14 Chapters to deeply display the global Carcinoembryonic Antigen (CEA) market.1 Carcinoembryonic Antigen (CEA) Market Overview2 Company Profiles3 Global Carcinoembryonic Antigen (CEA) Market Competition, by Players4 Global Carcinoembryonic Antigen (CEA) Market Size by Regions5 North America Carcinoembryonic Antigen (CEA) Revenue by Countries6 Europe Carcinoembryonic Antigen (CEA) Revenue by Countries7 Asia-Pacific Carcinoembryonic Antigen (CEA) Revenue by Countries8 South America Carcinoembryonic Antigen (CEA) Revenue by Countries9 Middle East and Africa Revenue Carcinoembryonic Antigen (CEA) by Countries10 Global Carcinoembryonic Antigen (CEA) Market Segment by Type11 Global Carcinoembryonic Antigen (CEA) Market Segment by Application12 Global Carcinoembryonic Antigen (CEA) Market Size Forecast (2021-2025)13 Research Findings and Conclusion14 AppendixPurchase the complete Global Carcinoembryonic Antigen (CEA) Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-31935Other Reports by DecisionDatabases.com:Global Rapid Tests Market 2020 by Company, Regions, Type and Application, Forecast to 2025Global Anti-microbial/Anti-fungal Tests Market 2020 by Company, Regions, Type and Application, Forecast to 2025Global Hepatitis Viruses Rapid Tests Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.
DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.
We provide intellectual, precise and meaningful data at a lightning speed.For more details:DecisionDatabases.comE-Mail: [email protected]: +91 9028057900Web: https://www.decisiondatabases.com/
Industry InsightsThe global Carcinoembryonic Antigen (CEA) market is expected to reach USD 2.56 Billion by 2022, which is anticipated to grow at a CAGR of more than 6.6% during the forecast period.
The market is expected to witness significant growth in the coming few years owing to various key attributes such as growing incidence of cancer and technological advancement regarding the development of novel biomarkers.
Furthermore, increased consumption of alcohol, less physical activity, unhealthy diet, and rapidly changing lifestyle also contribute in the growth of colorectal cancer in the recent years.Breast cancer is another segment experiencing significant growth owing to the factors such as rising female population above 50 years, advancements in biomarkers and increase in number of patients undertaking hormone replacement therapy (HRT), and breast augmentation & reconstruction surgery.
Moreover, other breast related diseases such as infections, lesions, and fibrocysts are also expected to contribute towards the growth in early diagnosis.Regional InsightRegional segments of CEA market include North America, Europe, Asia Pacific, Latin America and MEA.
In 2016, North America dominate the regional market pertaining to various key attributes such as increasing patient awareness, rising incidences of cancer, favorable reimbursement policies, and presence of advanced healthcare infrastructure.
According to American Cancer Society in 2017, approximately 1,688,780 new cases of cancer were estimated in the U.S.Asia Pacific region is expected to grow at lucrative rates during the forecast period owing to the factors such as increasing prevalence of cancer in emerging economies such as Brazil, Russia, India, and China, favorable government initiatives, and significant presence of local players will drive the growth of the market in this region.
The global Carcinoembryonic Antigen (CEA) market is expected to reach USD 2.56 Billion by 2022, which is anticipated to grow at a CAGR of more than 6.6% during the forecast period.
The market is expected to witness significant growth in the coming few years owing to various key attributes such as growing incidence of cancer and technological advancement regarding the development of novel biomarkers.
Furthermore, increased consumption of alcohol, less physical activity, unhealthy diet, and rapidly changing lifestyle also contribute in the growth of colorectal cancer in the recent years.Breast cancer is another segment experiencing significant growth owing to the factors such as rising female population above 50 years, advancements in biomarkers and increase in number of patients undertaking hormone replacement therapy (HRT), and breast augmentation & reconstruction surgery.
Moreover, other breast related diseases such as infections, lesions, and fibrocysts are also expected to contribute towards the growth in early diagnosis.Regional InsightRegional segments of CEA market include North America, Europe, Asia Pacific, Latin America and MEA.
In 2016, North America dominate the regional market pertaining to various key attributes such as increasing patient awareness, rising incidences of cancer, favorable reimbursement policies, and presence of advanced healthcare infrastructure.
According to American Cancer Society in 2017, approximately 1,688,780 new cases of cancer were estimated in the U.S.Asia Pacific region is expected to grow at lucrative rates during the forecast period owing to the factors such as increasing prevalence of cancer in emerging economies such as Brazil, Russia, India, and China, favorable government initiatives, and significant presence of local players will drive the growth of the market in this region.
Global Carcinoembryonic Antigen Market Research Report: Information by Application (Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Lung Cancer, and Others), End User (Hospitals and Clinics, Diagnostic Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025Market HighlightsCarcinoembryogenic antigen (CEA) is a group of glycoproteins which are produced during the fetal developmental stages by gastrointestinal tissues.
CEA is responsible for cell adhesion.
Thus, CEA based diagnostic assays are used for the detection of such cancers and to check the treatment efficiency during the therapeutic period by a physician.Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/772In 2017, studies of the NCBI suggested that the global burden of colorectal cancer will increase by 60%, leading to 2.2 million new cancer cases and 1.1 million deaths by 2030.
This will increase the colorectal cancer diagnostic demands, thereby propelling the market growth.Increasing prevalence of cancer, rising healthcare expenditures, and developing diagnostic technologies will boost the global market during the forecast period.
However, risk of infection and hematoma, lack of awareness and medical services in the developing countries will restrain the market growth during the assessment period.Market PlayersSome of key players profiled in the report are Lee BioSolutions, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated., Correlogic Systems, Inc, Genway Biotech, Inc., Abbott., RayBiotech, Inc., Abcam plc., Biocare Medical, LLC, and Biocare Medical, LLC.Regional AnalysisThe Americas account for the largest share in the carcinoembryogenic antigen market.
The Americas mainly include countries like the U.S. and Canada.
